PV CHRONICLE

The official newsletter of DTRAS GLOBAL

IN THIS ISSUE

Can AI Replace Case Processors? The Future of Touchless PV Systems

by Dr. Vanishree Rao

Pharmacovigilance (PV) plays a crucial role in ensuring drug safety and regulatory compliance by continuously monitoring, detecting, and reporting adverse drug reactions (ADRs). Traditionally, this process has been heavily dependent on human expertise, requiring manual case processing, data entry, validation, narrative writing, and compliance checks. However, with the rise of Artificial Intelligence (AI) and automation, the industry is undergoing a major transformation.

However, despite AI's capabilities, critical challenges remain—such as regulatory trust, ethical considerations, explainability, and AI's ability to handle complex medical reasoning.

Can AI fully replace case processors, or will the future of PV rely on a hybrid human-AI model? This newsletter explores the latest AI advancements, regulatory concerns, industry adoption trends, and the future of touchless PV systems.

The AI Revolution in Case Processing

by Dr. Vishnu Mohandas

Pharmacovigilance (PV) plays a critical role in safeguarding public health, ensuring that pharmaceutical products undergo continuous monitoring for adverse drug reactions (ADRs) and safety risks. Traditionally, PV case processing has been a labor-intensive and time-consuming process, requiring skilled professionals to manually extract data, assess case validity, write narratives, and ensure compliance with global regulatory standards. Given the sheer volume of Individual Case Safety Reports (ICSRs) being reported worldwide, the industry has long sought ways to streamline operations, improve efficiency, and reduce costs.

With the rise of Artificial Intelligence (AI), Natural Language Processing (NLP), and automation, the concept of "touchless pharmacovigilance" has emerged—where AI-driven systems take over data extraction, case processing, medical coding, and even narrative generation with minimal human intervention. This breakthrough technology promises to revolutionize pharmacovigilance by offering:

- Faster Turnaround Times – AI-driven automation can process ICSRs 70% faster than traditional methods.

- Enhanced Data Accuracy – AI reduces human errors, misclassifications, and inconsistencies in case assessments.

- Significant Cost Savings – Automating manual case processing leads to a dramatic

The growing adoption of AI-powered case processing is already transforming the way pharmaceutical companies, contract research organizations (CROs), and regulatory agencies handle drug safety data.

However, despite AI's remarkable capabilities, several challenges remain—including regulatory acceptance, medical reasoning limitations, AI interpretability, and ethical considerations.

The key question now is: Can AI completely replace human case processors, or will the future of pharmacovigilance require a hybrid model where AI and humans work together?

While AI has proven to be an efficient tool for case triage, duplicate detection, and automated reporting, the need for expert medical judgment and nuanced decision-makingstill presents a major barrier to full automation.

As the industry moves towards a touchless PV system, striking the right balance between automation and human expertise will be essential.

Key Highlights of AI in Case Processing

by Dr. Vishnu Mohandas

a) Accelerating Case Processing and Reducing Turnaround Time

Traditional pharmacovigilance workflows are highly manual and time-intensive, requiring skilled professionals to extract, validate, analyze, and submit ICSRs to regulatory agencies. Case processing can take anywhere from 6 to 10 hours per report, creating backlogs and delays in adverse event reporting. With AI-powered automation, case processing time can be reduced by up to 70%. AI systems can:

- Extract relevant data from unstructured sources like medical records, emails, and call center transcripts.
- Automatically classify cases based on severity and regulatory requirements.
- Pre-fill case reports with structured, regulatory-compliant data.
- Perform real-time case triaging for faster prioritization of serious adverse events.

By significantly reducing turnaround times, AI enables faster regulatory submissions, ensuring that drug safety signals are detected and acted upon more rapidly.

b) Improving Data Accuracy and Minimizing Human Errors

Human errors in pharmacovigilance case processing—such as misclassification, incorrect data entry, and missing information—can lead to regulatory non-compliance and impact patient safety. AI reduces the risk of human errors by:

- Standardizing medical terminology using AI-driven Medical Dictionary for Regulatory Activities (MedDRA) coding.
- Detecting duplicates in adverse event reports, preventing redundant case submissions.
- Ensuring data completeness by cross-verifying missing fields before case submission.

Using NLP to extract key information from physician notes, lab reports, and electronic health records (EHRs). AI's ability to process vast datasets with high precision and minimal variability

C) Enhancing Cost Efficiency and Resource Optimization

Pharmaceutical companies and contract research organizations (CROs) spend millions of dollars annually on manual case processing, employing large teams of case processors, medical reviewers, and compliance specialists. AI automation reduces operational costs by:

- Decreasing manpower needs for repetitive tasks like data entry and validation.
- Lowering case processing costs by replacing manual workflows with automated pipelines.
- Optimizing resource allocation, allowing human experts to focus on complex case assessments rather than routine tasks.

By implementing AI in case processing, companies can achieve cost savings of up to 50%, redirecting financial resources toward signal detection, benefit-risk assessment, and proactive safety monitoring.

Key Highlights of AI in Case Processing

by Dr. Vishnu Mohandas

d) AI-Driven Narrative Writing and Case Summarization

A critical part of ICSR processing is the case narrative, which provides a structured summary of an adverse event, including patient details, suspected drugs, adverse reactions, and medical history. Traditionally, case narratives require significant human effort and medical expertise. Generative AI models, such as GPT-based and NLP-driven solutions, can:

- Auto-generate case narratives based on structured data inputs.
- Summarize key case details using AI-driven natural language generation (NLG).
- Ensure narrative consistency across multiple case reports.

However, regulatory agencies have yet to fully approve AI-generated narratives, as human judgment is still required to verify medical context and ensure regulatory alignment.

e) AI in Causality Assessment and Signal Detection

Determining whether a drug caused an adverse event requires expert medical evaluation, statistical analysis, and pattern recognition. AI-driven causality assessment models use:

- Machine learning algorithms trained on historical ICSR data.
- Bayesian networks and decision trees to assess causal relationships.
- Real-time signal detection tools that monitor trends across FAERS, VigiBase, and EudraVigilance.

While AI is highly effective at identifying potential safety signals, human experts are still required to interpret findings, assess confounders, and validate clinical relevance.

f) Regulatory Challenges and Trust in AI-Based Case Processing

Despite AI's advantages, global regulatory agencies remain cautious about fully automated pharmacovigilance. Key regulatory concerns include:

- Transparency and Explainability – AI models operate as "black boxes," making it difficult to explain how decisions are made.
- Validation and Compliance – Regulatory bodies like FDA, EMA, and MHRA require stringent validation of AI models before they can be used for case processing.
- Ethical Considerations – AI-driven case processing must ensure patient privacy, data security, and unbiased decision-making.
- Human Oversight Requirements – Current regulations mandate that qualified professionals review and approve ICSR submissions, limiting AI's ability to function autonomously.

As AI adoption grows, regulatory frameworks will need to evolve to accommodate AI-driven pharmacovigilance workflows while maintaining patient safety and compliance.

AI vs. Human Case Processing

by Dr Padmavathy O

Pharmacovigilance (PV) is a critical function in the pharmaceutical industry, ensuring the safety of drugs by monitoring and reporting adverse drug reactions (ADRs). Traditionally, human case processors have handled Individual Case Safety Reports (ICSRs), applying their expertise in medical data interpretation, narrative writing, regulatory compliance, and causality assessment. However, AI-driven automation is rapidly transforming this landscape by accelerating processes, reducing costs, and minimizing human errors. Let's explore detailed, side-by-side comparison of AI and human case processors, evaluating their strengths, limitations, and the most viable path forward for the industry.

1. Speed and Efficiency: AI's Advantage

Human Case Processing:

- Traditional case processing is highly manual and time-consuming, requiring 6–10 hours per case.
- Humans must extract, verify, analyze, and enter data into regulatory reporting systems.
- High workload and fatigue increase the likelihood of delays and backlogs.
- Time constraints affect the timeliness of safety reporting, impacting regulatory compliance.

AI-Powered Case Processing:

- AI-driven automation can process cases in minutes, cutting turnaround times by up to 70%.
- AI extracts and structures data from EHRs, emails, call center transcripts, and safety databases automatically.
- Real-time case triaging and AI-driven prioritization accelerate regulatory submissions.
- Automated workflows ensure 24/7 case processing, eliminating human-dependent delays.

Verdict: AI significantly outperforms humans in speed and efficiency, enabling faster adverse event reporting and regulatory compliance.

## 2. Data Accuracy and Error Reduction: AI vs. Human Judgment

Human Case Processing:

- Prone to human errors in data entry, classification, and MedDRA coding.
- Inter-individual variability in assessing adverse event severity and causality.
- Fatigue and cognitive biases may lead to inconsistencies in case processing.

AI-Powered Case Processing:

- AI eliminates human errors by ensuring consistent data extraction, validation, and classification.
- NLP-driven AI models standardize MedDRA and WHO-DD coding, reducing variability.
- AI-powered duplicate detection systems prevent redundant case submissions.
- Machine learning algorithms detect missing data fields and auto-populate them accurately.

Verdict: AI provides higher accuracy and standardization, significantly reducing the risk of manual errors and inconsistencies.

AI vs. Human Case Processing

by Dr Padmavathy O

3. Narrative Writing and Case Summarization: AI's Growing Capabilities

Human Case Processing:
- Medical professionals write detailed case narratives, ensuring clinical context and regulatory compliance.
- Human expertise allows for interpretation of complex medical histories, co-medications, and confounding factors.
- Narrative writing is time-intensive and subject to variability between processors.

AI-Powered Case Processing:
- AI-driven Natural Language Generation (NLG) can auto-generate case narratives based on structured data.
- NLP models summarize key medical details, reducing manual workload.
- AI-generated narratives ensure consistency across multiple case reports.
- AI struggles with contextual nuances, rare medical conditions, and multi-drug interactions.
- AI-generated narratives lack human clinical reasoning and expert judgment.
- Regulatory agencies require human oversight to validate AI-generated case summaries.

Verdict: While AI can automate case narrative generation, human review is still essential to ensure medical accuracy and compliance.

4. Causality Assessment: AI vs. Human Expertise

Human Case Processing:
- Medical reviewers assess causality based on clinical experience, patient history, and literature evidence.
- Humans consider complex relationships between drugs, co-morbidities, and confounding factors.
- Decisions may be subjective and vary between experts.

AI-Powered Case Processing:
- AI models analyze historical safety data, FAERS, VigiBase, and EudraVigilance reportsto predict causality.
- Bayesian networks, decision trees, and machine learning models identify patterns in large datasets.
- AI improves signal detection by continuously analyzing vast amounts of real-world data.
- AI struggles with rare or unexpected ADRs due to limited training data.
- AI lacks the ability to apply clinical reasoning beyond data-driven correlations.
- AI cannot replace expert medical judgment in borderline or ambiguous cases.

Verdict: AI enhances causality assessment but cannot fully replace human medical expertise in complex evaluations.

AI vs. Human Case Processing

by Dr Padmavathy O

5. Compliance and Regulatory Acceptance: Human Oversight Still Required

Human Case Processing:
- Regulatory bodies require human oversight for ICSR validation and approval.
- Medical experts ensure compliance with evolving global PV regulations.
- Humans interpret regulatory expectations that AI models may not fully understand.

AI-Powered Case Processing:
- AI automates compliance checks against regulatory guidelines (FDA, EMA, MHRA, PMDA).
- AI-driven audit trails ensure complete documentation for inspections.
- AI assists with expedited reporting, risk minimization measures, and aggregate reports.
- Regulatory agencies do not yet fully approve AI-generated ICSRs without human validation.
- AI must be continuously trained on evolving regulatory changes.

Verdict: AI can streamline regulatory compliance, but human expertise is still required to ensure full adherence to global safety regulations.

6. Cost Efficiency and Resource Optimization

Human Case Processing:
- High operational costs due to the need for large pharmacovigilance teams.
- Resource-intensive processes requiring case processors, medical reviewers, and compliance specialists.
- Scalability is limited, requiring additional workforce during high case volumes.

AI-Powered Case Processing:
- AI automation reduces case processing costs by up to 50%.
- Companies can allocate human resources to higher-value activities like risk assessment and regulatory strategy.
- AI enables scalability without proportional increases in manpower.

Verdict: AI is more cost-effective and scalable, reducing reliance on large human workforces.

Final Verdict: AI vs. Human Case Processors—Who Wins?

by Dr Padmavathy O

Feature	Human Case Processing	AI-Powered Case Processing
Speed & Efficiency	Slower, labour intensive	Faster (70 % reduction in TAT)
Data Accuracy	Prone to errors & variability	High Accuracy, standardised data processing
Narrative Writing	Expert-driven, clinically rich	Requires human validation but faster, less errors and auto updates
Causality Assessment	Medical expertise required	Lacks Reasoning, but scenario and pattern recognition makes it robust
Regulatory Compliance	Required for validation	Ai enhances but need human oversight
Cost Efficiency	High manpower costs	Reduces cost by 50 %
Scalability	Limited, needs more staff for high volumes	Highly scalable, 24/7 case processing

Rather than replacing human case processors entirely, AI will augment human workflows, creating a hybrid model where AI handles routine tasks while humans focus on high-value activities. The future of pharmacovigilance lies in a collaborative AI-human approach, ensuring both efficiency and clinical integrity in global drug safety monitoring.

Can AI-Generated Reports Be Trusted?

by Dr. Vikram Singh

The use of Artificial Intelligence (AI) in pharmacovigilance (PV) is revolutionizing how Individual Case Safety Reports (ICSRs) are processed. AI-driven tools can extract adverse event data from multiple sources, structure information, generate case narratives, and even perform causality assessments. However, one of the most critical concerns in this transformation is whether AI-generated case reports can be fully trusted.

While AI offers unparalleled speed, consistency, and cost efficiency, there are key challenges regarding data accuracy, medical reasoning, regulatory compliance, and ethical considerations. Lets explore the capabilities, limitations, and potential risksassociated with AI-generated case reports in PV.

The Promise of AI-Generated Case Reports

Speed & Efficiency
- AI-driven case processing significantly reduces the time required to handle ICSRs. Traditional case processing can take 6–10 hours per case, while AI can process multiple cases within minutes by:
- Extracting structured and unstructured data from electronic health records (EHRs), patient reports, and call center logs.
- Automating duplicate detection, validation, and data standardization.
- Generating narratives using Natural Language Processing (NLP) models trained on historical cases.

Consistency & Reduced Human Error
Manual case processing is subject to human variability, leading to inconsistencies in case classification, coding, and narrative generation. **AI ensures**:
- Standardized narratives across reports, reducing subjective bias.
- Automated MedDRA coding for adverse events, making the process more efficient.
- Better duplicate detection, minimizing redundant case submissions.

Cost Reduction & Scalability
Pharmaceutical companies spend millions on PV operations due to the high manpower costsassociated with case processing. AI:
- Cuts labor costs by up to 50%.
- Processes cases 24/7 without fatigue.
- Handles large case volumes without requiring additional staff.

Can AI-Generated Reports Be Trusted?

by Dr. Vikram Singh

The Challenges of AI-Generated Case Reports

Medical Judgment & Clinical Reasoning

AI excels in data processing but struggles with clinical reasoning. A case processor doesn't just extract information—they assess causality, severity, and clinical significance. **AI lacks:**

- The ability to interpret complex medical cases where multiple drugs, comorbidities, or off-label uses are involved.
- Medical intuition to flag potential safety concerns that may not be explicitly stated in the data.
- Contextual understanding, especially when dealing with rare or emerging adverse events.

Data Accuracy & Potential Bias

AI models learn from historical datasets, which may introduce:

- Bias in case processing, leading to incorrect case prioritization.
- Incomplete or misleading narratives, as AI-generated text may lack context.
- Over-reliance on structured data, failing to capture nuances in physician notes or patient-reported outcomes.

Regulatory Compliance & Legal Considerations

Regulatory agencies such as FDA, EMA, and MHRA require human oversight in case processing. Key compliance concerns include:

- Auditability – Can AI-generated reports be traced back to source data?
- Explainability – Can AI decisions be justified if challenged by regulators?
- Validation – Are AI-generated narratives compliant with Good Pharmacovigilance Practices (GVP)?
- Many regulators remain skeptical about allowing AI to fully automate case processing without human validation.

The Hybrid Model: AI + Human Oversight

Given AI's strengths and weaknesses, the most realistic approach to case processing is a hybrid model where:

- AI handles routine cases with clear, structured data.
- Human experts validate complex cases, ensuring medical judgment is applied.
- AI-generated narratives are reviewed and edited before submission.
- AI assists in causality assessment, but human reviewers make final decisions.

Can AI-Generated Reports Be Trusted?

by Dr. Vikram Singh

Future of AI in Case Processing: Can AI Ever Fully Replace Humans?

While AI is transforming PV, complete automation remains unlikely in the near future due to:

- Regulatory requirements for human validation.
- The need for clinical reasoning in complex cases.
- The importance of ethical considerations in drug safety.

However, as AI models improve with explainable AI (XAI), causal inference, and knowledge graphs, we may see:

- AI taking over 80-90% of routine case processing within 5–10 years.
- Greater regulatory acceptance of AI-generated case reports.
- A new role for PV professionals as AI supervisors, ensuring data integrity and compliance.

Final Verdict: Can AI-Generated Case Reports Be Fully Trusted?

AI is highly effective in automating case processing but not yet capable of fully replacing human judgment. While AI can:

- Process cases faster and with fewer errors,
- Generate structured narratives and automate coding,
- Reduce costs and increase scalability, but it still requires human oversight for medical decision-making, compliance, and complex case assessments.

The Future of Touchless PV Systems

by Dr. Balaji

The concept of Touchless Pharmacovigilance (PV) is no longer science fiction—it is rapidly becoming a reality. With AI-driven automation, advanced machine learning (ML), and Natural Language Processing (NLP), the pharmacovigilance industry is on the brink of a transformation where case processing, signal detection, aggregate reporting, and compliance monitoringcan be done with minimal or no human intervention.

Imagine a world where:

- AI-powered bots extract and validate Individual Case Safety Reports (ICSRs) in real time.
- Machine learning models detect safety signals before they escalate into major drug safety concerns.
- Automated regulatory submissions eliminate delays and human errors.

This shift towards touchless PV is not just about efficiency—it's about enhancing drug safety, reducing costs, and ensuring regulatory compliance faster than ever before.

How Does Touchless Pharmacovigilance Work?

AI-Driven ICSR Processing: AI automates case intake from multiple sources (EHRs, patient reports, call centers, literature), structures the data, and generates narratives without human input.

Real-Time Signal Detection: Advanced AI models continuously scan databases like FAERS, VigiBase, and EudraVigilance, identifying emerging safety trends with predictive analytics.

Regulatory Automation: AI ensures compliance with FDA, EMA, MHRA, and PMDAregulations by auto-generating and submitting reports in E2B(R3) formats.

Blockchain for Data Integrity: Secure, tamper-proof patient safety data storage ensures transparency and auditability.

 AI-Powered Risk Management: Automated Risk Management Plans (RMPs) proactively suggest safety measures based on real-world data.

The Benefits of Touchless PV

Speed: Reduces case processing time by up to 70%, enabling real-time decision-making.

Scalability: Handles millions of cases annually without expanding human workforce.

Cost Savings: Reduces manual effort and compliance costs by nearly 50%.

Data Accuracy: AI-driven case validation eliminates human bias and errors.

24/7 Monitoring: AI never sleeps—it continuously monitors drug safety signals across global databases.

The Future of Touchless PV Systems

by Dr. Balaji

Can Touchless PV Be Fully Autonomous?

While AI can automate 80-90% of routine PV tasks, complete autonomy is still a work in progress due to:

- ***Regulatory hesitations***—Agencies still require human oversight for case validation.
- ***Medical reasoning limitations***—AI lacks deep clinical judgment for complex cases.
- ***Ethical concerns***—Ensuring transparency and fairness in AI-driven drug safety decisions.

What's Next for AI-Driven PV?

- AI-driven PV will become more explainable, addressing regulatory concerns.
- Integration with Wearable Devices & Real-World Data (RWD) will provide instant safety insights.
- AI-powered conversational bots may replace call centers for adverse event reporting.
- Regulatory agencies may standardize AI-driven PV compliance frameworks, accelerating adoption.
- *The future is clear*: Touchless Pharmacovigilance is not just an option—it's the next evolution of drug safety.

D-TRAS GLOBAL
Swiftly Innovative

Takeaways & Final Thoughts

by Dr. Balaji

AI is Reshaping PV, But Full Automation is Not Here Yet!

Artificial Intelligence is undoubtedly transforming pharmacovigilance (PV) by reducing manual workload, improving efficiency, and minimizing errors in case processing. AI-powered tools are already proving their ability to extract, validate, and analyze Individual Case Safety Reports (ICSRs) at unprecedented speeds. Companies adopting these technologies are experiencing up to a 70% reduction in processing time and significant cost savings. However, despite these advancements, full automation remains out of reach—at least for now. Human oversight is still essential for ensuring data integrity, medical reasoning, and compliance with global regulatory standards.

Key Takeaways

AI Enhances Efficiency, But Humans Ensure Accuracy
While AI can process ICSRs faster than ever before, regulatory agencies still require human review to validate case narratives, assess causality, and ensure medical accuracy. AI-driven models may structure data flawlessly, but they lack the deep clinical reasoning and contextual understanding that experienced pharmacovigilance professionals bring.

Regulatory Bodies Prioritize Explainability & Ethical AI Use
The FDA, EMA, MHRA, and PMDA are closely monitoring AI adoption in PV, emphasizing transparency, auditability, and ethical AI deployment. AI must not only be efficient but also explain how and why it reaches its conclusions—ensuring compliance with Good Pharmacovigilance Practices (GVP).

The Future Lies in a Hybrid Model
Rather than replacing case processors entirely, AI is evolving as a co-pilot, streamlining workflows while human experts provide oversight, ensure compliance, and make final clinical judgments. This hybrid approach balances efficiency with regulatory trust—allowing AI to handle routine tasks while professionals focus on high-risk cases and strategic safety decisions.

The Big Question: What's Next?
- Will regulatory agencies approve AI-generated ICSRs without human validation in the next five years?
- Can AI achieve complete autonomy while maintaining patient safety and regulatory compliances

As AI technology advances, industry leaders, regulators, and healthcare professionals must work together to define the future of AI-driven pharmacovigilance. One thing is certain—AI isn't replacing humans entirely, but it is redefining their roles. The journey toward touchless PV is just beginning. Are you ready to embrace the future?

D-TRAS GLOBAL
Swiftly Innovative

CART.ai